Please login to the form below

Not currently logged in
Email:
Password:

Boehringer Ingelheim and Lilly launch diabetes education campaign

Follows the partnership’s filing of its SGLT-2 inhibitor for European approval

Boehringer Ingelheim and Lilly have developed a joint education campaign about the role of sodium glucose co-transporters (SGLT) in maintaining blood sugar balance for type 2 diabetes patients.

The campaign has been designed to provide healthcare professionals (HCPs) with a better understanding of the emerging science of using SGLTs to maintain glucose homeostasis, or blood sugar balance, which enables glucose entering the kidneys to find its way back into the bloodstream instead of being passed in the urine.

The initiative includes a microsite - www.sglt.com - featuring a short educational video, Glucose Perspectives, which was created by the Royal Society for the encouragement of Arts, Manufacturing and Commerce (RSA). Viewers are invited to sign up for further learning options that will be offered throughout the year.

“The contribution of insulin resistance and impaired beta-cell function in the physiopathology of type 2 diabetes mellitus has been extensively studied,” said Christophe Arbet-Engels, MD, PhD, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim.

“The contributing role of persistently high glucose levels in the progression of type 2 diabetes has led to the need for a better understanding of how glucose is reabsorbed by the kidneys.

“The Boehringer Ingelheim and Lilly Diabetes alliance is very pleased to offer healthcare professionals an educational resource they can use at their convenience to gain greater knowledge of this process.”

Germany-headquartered Boehringer Ingelheim and US-based Eli Lilly announced a diabetes alliance at the beginning of 2011, which has focused on three pipeline compounds representing several of the largest treatment classes.

Earlier this year, the partnership filed its new SGLT-2 inhibitor, Empagliflozin, for European approval.

8th May 2013

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics